What Megecat Treats: Main Uses and Benefits

Megecat, which contains megestrol acetate, is generally used to address two distinct, major therapeutic domains. One primary use is the supportive management of severe wasting and loss of appetite. This is considered relevant for adult patients, particularly those with a diagnosis of Acquired Immunodeficiency Syndrome (AIDS), who are experiencing cachexia or unexplained, significant weight loss. The medication is applied in addressing this serious condition by providing an appetite-stimulating effect, which may support increased food consumption.

This supportive function is relevant in clinical settings where the patient requires additional assistance with nutritional support and assisting with maintaining functional stability. The drug is commonly used to help with managing symptoms of conditions including advanced breast cancer and advanced endometrial cancer that are recurrent or metastatic. The overall therapeutic benefit assists with easing the overall symptom load caused by the progressive disease, which contributes to improved day-to-day comfort.

“This medication is applied across domains where additional symptomatic support is needed, focusing on nutritional status and palliative care.”

Quick Fact: Supportive Relief for Severe Appetite Loss

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Megecat — Official Regulatory Information

Eligibility scope

• Populations for whom use is allowed (as stated in label): Adult patients (age ge 18 years) for the approved indications.
• Populations for whom use is not recommended (if applicable): Lactating/nursing mothers; pregnant individuals during the first four months of pregnancy.
• Populations for whom use is contraindicated: Patients with known hypersensitivity to the drug; known or suspected pregnancy; active thromboembolic disorder; and undiagnosed abnormal genital bleeding.
• Age-related eligibility rules: Safety and effectiveness are not established in pediatric patients. Older adults require cautious dose selection, particularly related to potential for decreased renal function.
• Condition-specific eligibility rules: Use with caution in patients with renal impairment, hepatic impairment, and diabetes mellitus due to potential for exacerbation or increased risk of toxic reactions.
• Pregnancy and lactation eligibility status (if explicitly documented): Pregnancy is contraindicated. Lactation is not recommended; nursing should be discontinued.
• Eligibility-related restrictions: Use requires caution in patients with a history of thromboembolic disease or conditions susceptible to fluid retention. Adrenal insufficiency must be considered during or after chronic therapy.

Eligibility Classifications (High-Level)

Resulting Eligibility Structure

Official eligibility statements:

• Contraindicated in known or suspected pregnancy.
• Safety and effectiveness are not established in pediatric patients.
• Use with caution in patients with impaired renal function or history of thromboembolic disease.

Connection to the overall eligibility profile: Official regulatory documents define Megecat's eligibility by formally prohibiting use in high-risk populations, such as pregnant women or those with active thromboembolic disorders. The medicine's use is further restricted to the adult population due to its not established status in children. Patients with comorbidities like diabetes or renal impairment are classified for restricted use under careful surveillance.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Megestrol acetate, strictly based on governmental regulatory prescribing information. The profile establishes which co-administered substances are affected and details specific usage cautions.

Documented Pharmacokinetic Interactions

Official Interaction-Related Cautions and Constraints

The regulatory profile identifies two key interaction-related constraints and cautions:

• Population-Specific Renal Caution: The risk of toxic reactions may be greater in elderly patients and those with impaired renal function. This is due to the drug's substantial renal excretion, a factor that must be considered in therapeutic management.
• Pharmacodynamic Potential: Due to the documented risk of impaired glucose tolerance and new-onset diabetes, a potential for pharmacodynamic antagonism exists with concurrent anti-diabetic agents.
• Drug-Food Interaction: The absorption of the original formulation of Megestrol acetate is significantly increased when taken with a high-fat meal. Newer formulations may be taken without regard to meals.

Megecat functions primarily as a high-affinity agonist at the nuclear Progesterone Receptor (PR) and, to a lesser extent, the Glucocorticoid Receptor (GR). Upon binding, the ligand-receptor complex translocates into the nucleus, modulating the transcription of specific target genes by binding to hormone response elements in DNA. This genomic signaling pathway alters the synthesis of regulatory proteins involved in cell proliferation and metabolism. Systemically, activation of the PR and GR results in anti-gonadotropic effects by suppressing the release of Luteinizing Hormone (LH) from the anterior pituitary gland, which subsequently reduces endogenous estrogen synthesis. Furthermore, the molecular activity may interfere with the production or action of catabolic mediators such as pro-inflammatory cytokines, specifically inhibiting Tumor Necrosis Factor-alpha and Interleukins. The resulting modulation includes an up-regulation of Neuropeptide Y (NPY) levels in the hypothalamus, a peptide associated with central feeding regulation, contributing to systemic anabolic shifts.

How to Use Megecat

Megecat, which contains megestrol acetate, is used according to specific instructions detailed in prescribing information. The medicine is administered exclusively by the oral route, available as either tablets or an oral suspension.

Official Dosing Regimens

The required dosage and frequency depend strictly on the condition being addressed:

These regimens are established for the clinical management of the specified conditions.

Administration and Use Conditions

Prescribing information includes procedural steps for proper administration. If using the oral suspension, the container must be shaken well before each dose to ensure accurate measurement. The two different suspension strengths (40 mg/mL and 125 mg/mL) are not substitutable on a milligram-for-milligram basis due to varying absorption characteristics. Furthermore, the score line on the 160 mg tablet is only for ease of swallowing and should not be used to divide the dose.

Use of megestrol acetate requires continuous administration for a defined period; for the palliative cancer setting, a minimum of two continuous months of treatment is required before the objective response can be appropriately assessed. Dosing for older adult patients is typically initiated cautiously, generally starting at the low end of the therapeutic range.

Research Evidence / Overview of Studies

Research has explored whether the drug, when used as a monotherapy, is associated with differences in patient outcomes. Studies investigated the drug’s observed biological impact.

• Studies examined whether the drug was associated with changes in the frequency and severity of acute episodes.
• Researchers assessed patient cohorts over a 12-month period and evaluated the maintenance of findings related to symptoms.
• Specific trials focused on different patient subgroups, including those with severe, refractory conditions.

Studies on Combination Treatment

Clinical trials have evaluated the relationship between this combination and changes in overall health measures, with research exploring findings related to disease progression markers.

• A Phase III randomized study evaluated the drug in combination with established first-line treatments.
• Studies examined different dosing regimens for the combination therapy to determine the most frequently used approach in the research setting.
• Analysis by researchers of subgroups included patients with co-existing conditions, with research examining its impact in older patient populations.

Special Populations and Safety

Research focusing on the drug's profile in specific patient groups addressed concerns regarding systemic absorption and interaction potential.

• The studies reviewed indicated that the drug was only used as a second-line treatment in pediatric trials, with research noting potential differences in results when combined with other agents.
• One large meta-analysis reported findings that differed when compared to placebo across a broad patient population, a finding that contributed to the overall body of evidence examined.
• The overall profile reported across most studies was noted by researchers, although investigators cautioned that long-term safety data remains limited.

Key Studies & References

1. Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
2. Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite (NCT00031707)

Common questions about Megecat (FAQ)

Q: Is Megecat only for temporary problems, or for long-term use?

Official product information states that the medicine is typically administered for a defined period, such as a minimum of two continuous months for the objective response to be assessed in some settings. Because chronic use is associated with hormonal effects, including the potential for adrenal suppression upon withdrawal, continuous long-term administration is a matter for ongoing surveillance and review by a healthcare professional.

Q: How long does it typically take for Megecat to start working?

Studies on megestrol acetate’s use for appetite and weight suggest that patient-reported increases in appetite are typically noted within approximately four weeks of starting treatment. However, measurable changes in weight are generally assessed later in treatment, around 12 weeks of continuous use.

Q: Are there any foods or drinks that should be avoided when using Megecat?

Official labeling indicates that the absorption of the original tablet formulation of megestrol acetate is significantly increased when taken with a high-fat meal. Newer oral suspension formulations are typically approved to be taken without regard to meals. Regulatory documents reviewed do not contain an explicit general warning regarding avoiding alcohol or specific common drinks.

Q: What does the research evidence say about Megecat's success rate in clinical trials?

Research reviewed by official bodies indicates the drug is associated with an increase in appetite reported by patients and a slight increase in weight compared to a placebo. Clinical trial data has reported a measurable increase in appetite compared to a placebo group.

Q: Does Megecat affect sleep or cause insomnia?

Official product information lists trouble sleeping (insomnia) as a potential side effect reported by some patients in clinical trials. This is considered one of the common side effects that can occur while taking the medicine.

Q: What is the official safety classification of Megecat?

The drug's active ingredient is officially classified as contraindicated in known or suspected pregnancy due to the potential for fetal harm. Official labels advise that women of childbearing potential should be informed of the need to avoid pregnancy while the medicine is in use.

Q: Does taking Megecat make a person drowsy or impair driving?

Regulatory documents list dizziness and a general feeling of weakness or tiredness as reported side effects. Regulatory documents note that caution should be exercised when driving or operating machinery if these side effects occur.

Q: Is Megecat a generic drug or a brand-name medicine?

The active ingredient in the medicine, megestrol acetate, is the generic name for the compound. Megecat is a specific preparation which may be available under original brand names (such as Megace) as well as various generic versions, depending on the specific formulation and country.

Q: Does Megecat have an effect on blood pressure?

Official documentation lists high blood pressure (hypertension) as a potential side effect experienced by some patients in clinical trials. The potential for this side effect is noted in official guidelines.

Storage and Disposal of Megestrol Acetate (Megecat)

Megestrol acetate tablets must be stored at controlled room temperature, specifically 25°C (77°F). Acceptable temperature excursions range from 15°C to 30°C (59°F to 86°F).

Required Storage Conditions

Child Safety and Waste Handling

As a mandatory precaution, this medicine must be kept out of the reach of children. For discarding unused or expired product, users should consult the official guidelines provided by the national health authority for the safe disposal of medicines.